About
Contact
Subscribe
e-Edition

Make Home Page

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

- Site search

Home
News
Sports
- Local Sports
- National Sports
Business
Opinion
A & E
Life
Features & Magazines
- WOMEN
- 2026 Readers' Choice Awards
Classifieds
Weather
Obituaries
2026 Readers' Choice Winners

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

1.510 -0.110 (-6.79%)

Delayed Quote Updated: 11:16 AM EDT, Oct 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Innate Pharma S.A. - American Depositary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer

June 03, 2022

From Innate Pharma S.A.

Via Business Wire

Outcome of Innate Pharma’s 2022 Annual General Meeting

May 20, 2022

From Innate Pharma S.A.

Via Business Wire

Innate Pharma to Participate in Upcoming Investor Conferences

May 11, 2022

From Innate Pharma SA

Via Business Wire

Innate Pharma Reports First Quarter 2022 Financial Results and Business Update

May 10, 2022

From Innate Pharma SA

Via Business Wire

Number of Shares and Voting Rights of Innate Pharma as of May 1, 2022

May 10, 2022

From Innate Pharma SA

Via Business Wire

Innate Pharma Establishes an At-The-Market (“ATM”) Program on Nasdaq

May 03, 2022

From Innate Pharma SA

Via Business Wire

Innate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update

May 03, 2022

From Innate Pharma SA

Via Business Wire

70 Biggest Movers From Friday ↗

May 02, 2022

Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners. Vaxxinity, Inc. (NASDAQ: VAXX)...

Via Benzinga

48 Stocks Moving In Friday's Mid-Day Session ↗

April 29, 2022

Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS. GTY Technology Holdings Inc. (NASDAQ:...

Via Benzinga

The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid ↗

April 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

28 Stocks Moving in Friday's Pre-Market Session ↗

April 29, 2022

Gainers Zymeworks Inc. (NASDAQ: ZYME) rose 40.3% to $6.97 in pre-market trading. Zymeworks 13D filing confirmed earlier reporting of offer letter from Blue Falcons for $10.50 per...

Via Benzinga

Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca

April 29, 2022

From Innate Pharma SA

Via Business Wire

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 20, 2022

April 08, 2022

From Innate Pharma SA

Via Business Wire

Innate Pharma Files Its 2021 Universal Registration Document (Document d’enregistrement universel) and 2021 Annual Report on Form 20-F

April 05, 2022

From Innate Pharma SA

Via Business Wire

Earnings Scheduled For March 24, 2022 ↗

March 24, 2022

Companies Reporting Before The Bell • iHuman (NYSE:IH) is likely to report earnings for its fourth quarter. • Pioneer Muni High Inc (NYSE:MAV) is expected to...

Via Benzinga

Innate Pharma Reports Full Year 2021 Financial Results and Business Update

March 24, 2022

From Innate Pharma SA

Via Business Wire

Innate Pharma FY 2021 Earnings Conference Call On March 24, 2022 At 09:00 AM ET ↗

March 22, 2022

Innate Pharma (NASDAQ:IPHA) will host a conference call at 09:00 AM ET on March 24, 2022, to discuss FY 2021 earnings results. How to Attend Innate Pharma (IPHA) Conference Call...

Via Benzinga

Innate Pharma Announces Conference Call and Webcast for Full Year 2021 Financial Results

March 17, 2022

From Innate Pharma SA

Via Business Wire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 10, 2022

Gainers Innate Pharma (NASDAQ:IPHA) stock increased by 13.7% to $3.32 during Thursday's pre-market session. The market value of their outstanding shares is at $264.6...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 07, 2022

Gainers

Via Benzinga

Number of Shares and Voting Rights of Innate Pharma as of February 1, 2022

February 15, 2022

From Innate Pharma SA

Via Business Wire

Innate Pharma to Participate in Upcoming Investor Conferences

February 04, 2022

From Innate Pharma SA

Via Business Wire

20 Stocks Moving in Tuesday's Pre-Market Session ↗

January 25, 2022

Gainers Aptorum Group Limited (NASDAQ: APM) shares rose 94.4% to $3.15 in pre-market trading after gaining around 10% on Monday. The FDA recently granted Orphan Drug Designation...

Via Benzinga

Number of Shares and Voting Rights of Innate Pharma as of January 1, 2022

January 24, 2022

From Innate Pharma S.A.

Via Business Wire

The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets ↗

January 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,...

Via Benzinga

Innate Pharma Obtains €28.7m in Non-Dilutive Financing in the Form of State Guaranteed Loans

January 05, 2022

From Innate Pharma SA

Via Business Wire

Innate Pharma to Participate in Upcoming Investor Conferences

January 04, 2022

From Innate Pharma SA

Via Business Wire

18 Stocks Moving in Monday's Pre-Market Session ↗

January 03, 2022

Gainers Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) rose 41.6% to $3.13 in pre-market trading after gaining around 8% on Friday. Armstrong Flooring, Inc. (NYSE: AFI...

Via Benzinga

Innate Pharma: First Patient Dosed in IPH6101/SAR443579 Phase 1/2 Clinical Trial in Various Blood Cancers

December 16, 2021

From Innate Pharma SA

Via Business Wire

Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity ↗

December 09, 2021

Innate Pharma SA's (NASDAQ: IPHA) data from the Phase 2 expansion cohort (cohort 3) evaluating the monalizumab triplet combination shows preliminary activity and an...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Opinion
Photo Galleries
Videos
Local Events
Classifieds
Obituaries

Services

About
Contact
Personnel
Advertise
Subscription Services
Promote Your Event
Dealer Locations
Email Alerts
Submission Forms

Contact Information

chroniclejournal.com
75 S. Cumberland Street
Thunder Bay, ON P7B 1A3
Phone: 807 343 6200
Email: circulation@chroniclejournal.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

All News about Innate Pharma S.A. - American Depositary Shares

Sections

Services

Contact Information

Follow Us